rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with RA meeting the 2010 ACR/EULAR Classification Criteria for RA Patients with an inadequate response to at least one csDMARD previously Patients aged 20 years or older at the informed consent for study participation Patients aged 65 years or older or those with a concurrent condition that can increase the risk of infection Patients starting abatacept therapy at the discretion of their primary physician
Exclusion criteria
Exclusion criteria: Patients treated with more than 3 types of biologics previously Patients with a history of hypersensitivity to any of the ingredients of the abatacept product Patients with a concurrent condition secondary to malignancy Patients with active infection Patients who are pregnant or breastfeeding, or those wishing pregnancy, childbearing, or breastfeeding Patients ineligible for study participation in the opinion of the investigator or subinvestigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achievement of remission (DAS28-ESR<2.6) or improvement of disease activity (delta-DAS28-ESR>1.2) at Month 6 | — |
Countries
Japan
Contacts
Public ContactYasuo Nagafuchi
Graduate School of Medicine, The University of Tokyo Department of Allergy and Rheumatology and Functional Genomics and Immunological Diseases
Outcome results
None listed